PriceTargets.com logo

LAVA Therapeutics - LVTX Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $14.33
  • Forecasted Upside: 691.90%
  • Number of Analysts: 3
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 3 Buy Ratings
  • 0 Strong Buy Ratings
$1.81 As of 05/26/2023 04:57 PM ET
▼ -0.08 (-4.23%)

This chart shows the closing price for LVTX by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New LAVA Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for LVTX and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for LVTX

Analyst Price Target is $14.33
▲ +691.90% Upside Potential
This price target is based on 3 analysts offering 12 month price targets for LAVA Therapeutics in the last 3 months. The average price target is $14.33, with a high forecast of $28.00 and a low forecast of $6.00. The average price target represents a 691.90% upside from the last price of $1.81.

This chart shows the closing price for LVTX for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 3 investment analysts is to buy stock in LAVA Therapeutics. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/6/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/6/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/4/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/2/2022
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/1/2022
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/1/2023
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
4/30/2023
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
5/30/2023

Latest Recommendations

  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
4/13/2023HC WainwrightReiterated RatingBuy$9.00Low
2/17/2023HC WainwrightReiterated RatingBuy$9.00N/A
11/22/2022JMP SecuritiesReiterated RatingBuy$6.00Low
10/25/2022HC WainwrightInitiated CoverageBuy$9.00Low
9/27/2022SVB LeerinkBoost TargetOutperform$25.00 ➝ $28.00Low
9/15/2022JMP SecuritiesInitiated CoverageOutperformLow
5/18/2022SVB LeerinkBoost TargetOutperform$25.00Low
4/27/2022SVB LeerinkReiterated RatingOutperformLow
11/16/2021SVB LeerinkLower TargetOutperform$24.00 ➝ $20.00Medium
8/17/2021SVB LeerinkLower TargetOutperform$26.00 ➝ $24.00Low
4/19/2021JPMorgan Chase & Co.Initiated CoverageOverweight$22.00Low
4/19/2021Jefferies Financial GroupInitiated CoverageBuy$23.00Low
4/19/2021SVB LeerinkInitiated CoverageOutperform$26.00Low
(Data available from 5/30/2018 forward)

News Sentiment Rating

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 1 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
11/1/2022
  • 1 very positive mentions
  • 1 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
Mentions as of
12/1/2022
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/31/2022
  • 2 very positive mentions
  • 1 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
Mentions as of
1/30/2023
  • 1 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
3/1/2023
  • 1 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
3/31/2023
  • 1 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
4/30/2023
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
5/30/2023

Current Sentiment

  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

  • No positive mentions tracked during this time.

Very Positive

  • No very positive mentions tracked during this time.
LAVA Therapeutics logo
LAVA Therapeutics N.V., a clinical-stage immuno-oncology company, focuses on developing cancer treatments. The company, through its Gammabody platform, develops a portfolio of novel bispecific antibodies to engage and leverage the potency and precision of gamma delta T cells to elicit an anti-tumor immune response and enhance outcomes for cancer patients. Its lead clinical-stage candidates are LAVA-051, which is in Phase 1/2a clinical trial for blood cancers, including chronic lymphocytic leukemia, multiple myeloma, and acute myeloid leukemia; and LAVA-1207 that is in Phase 1/2a clinical trial for metastatic castration-resistant prostate cancer. The company is also developing other Gammabody drug candidates, which include LAVA-1223, which targets the epidermal growth factor receptor (EGFR) for the treatment of selected solid tumors, as well as LAVA-1266 and LAVA-1278, which are preclinical candidates for the treatment of various hematologic malignancies. LAVA Therapeutics N.V. has a research collaboration and license agreement with Janssen Biotech, Inc. for the potential discovery and development of multi-specific antibody products that are directed to a specified target in various fields of use. The company was incorporated in 2016 and is headquartered in Utrecht, the Netherlands.
Read More

Today's Range

Now: $1.81
Low: $1.80
High: $1.89

50 Day Range

MA: $1.67
Low: $1.40
High: $1.90

52 Week Range

Now: $1.81
Low: $1.37
High: $7.38

Volume

10,700 shs

Average Volume

51,222 shs

Market Capitalization

N/A

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of LAVA Therapeutics?

The following sell-side analysts have issued research reports on LAVA Therapeutics in the last twelve months: HC Wainwright, JMP Securities, and SVB Leerink LLC.
View the latest analyst ratings for LVTX.

What is the current price target for LAVA Therapeutics?

3 Wall Street analysts have set twelve-month price targets for LAVA Therapeutics in the last year. Their average twelve-month price target is $14.33, suggesting a possible upside of 691.9%. SVB Leerink LLC has the highest price target set, predicting LVTX will reach $28.00 in the next twelve months. JMP Securities has the lowest price target set, forecasting a price of $6.00 for LAVA Therapeutics in the next year.
View the latest price targets for LVTX.

What is the current consensus analyst rating for LAVA Therapeutics?

LAVA Therapeutics currently has 3 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe LVTX will outperform the market and that investors should add to their positions of LAVA Therapeutics.
View the latest ratings for LVTX.

What other companies compete with LAVA Therapeutics?

Other companies that are similar to LAVA Therapeutics include NLS Pharmaceutics, Pharvaris, Qilian International Holding Group, Aclarion and Ainos. Learn More about companies similar to LAVA Therapeutics.

How do I contact LAVA Therapeutics' investor relations team?

The company's listed phone number is 31-85-016-3100 and its investor relations email address is [email protected]. The official website for LAVA Therapeutics is www.lavatherapeutics.com. Learn More about contacing LAVA Therapeutics investor relations.